Walmart Reaches $50 Million Settlement Over Alleged Illegal Dispensing of Opioids
The U.S. Department of Justice, in coordination with the Drug Enforcement Administration (DEA), has announced a $50 million settlement with Walmart Inc. to resolve allegations that Walmart pharmacies unlawfully filled thousands of invalid prescriptions for opioids and other controlled substances in violation of the Controlled Substances Act (CSA).
The settlement addresses allegations that Walmart pharmacies failed to adequately identify and prevent the dispensing of controlled substances when prescriptions contained significant warning signs or were issued by prescribers allegedly operating as “pill mills.”
DEA Assistant Administrator Cheri Oz said the settlement reinforces the responsibility pharmacies have to identify suspicious prescriptions and prevent the unlawful distribution of controlled substances. According to Oz, dispensing illegitimate opioid prescriptions can expose patients and communities to significant risks while weakening safeguards intended to prevent the diversion, misuse, and abuse of potentially addictive medications.
She added that the agreement addresses the conduct alleged by the government while establishing additional compliance requirements intended to strengthen Walmart's controls and reduce the likelihood of similar failures occurring in the future.
Associate Attorney General Stanley Woodward said the settlement reflects the Justice Department's commitment to enforcing laws designed to hold companies accountable when they dispense controlled substances. He emphasized that pharmacies are required to comply with federal safeguards and said commercial interests should never take precedence over measures intended to protect the public from the harms associated with opioid misuse.
Allegations of Invalid Prescriptions
The government's original complaint was filed on December 22, 2020, in the U.S. District Court for the District of Delaware and was subsequently amended in 2022.
According to the government's allegations, beginning as early as June 26, 2013, Walmart pharmacies filled prescriptions that were considered invalid under the Controlled Substances Act. The government alleged that this occurred through the actions of certain members of Walmart's corporate compliance team as well as individual pharmacists.
Federal prosecutors alleged that Walmart's compliance personnel were aware that some prescribers were operating as “pill mills,” yet prescriptions issued by those providers continued to be filled.
The government further alleged that Walmart's own pharmacists repeatedly alerted the company's corporate compliance team to questionable prescribing practices. These concerns were reportedly documented through thousands of internal “refusal-to-fill” forms, which pharmacists used to indicate that they believed particular prescriptions should not be dispensed.
Despite those warnings, the government alleged that Walmart's compliance operations did not consistently prioritize compliance with federal controlled-substance requirements. Instead, prosecutors said certain business objectives were given greater importance.
According to the complaint, one compliance director acknowledged in an email that focusing on “driving sales and patient awareness” was considered a better use of the time of certain market-level personnel than analyzing the refusal-to-fill reports submitted by pharmacists.
Pharmacists Allegedly Filled Prescriptions Despite Warning Signs
The government's allegations also involved individual Walmart pharmacists who were accused of dispensing prescriptions despite knowing or having reason to believe that the prescriptions were invalid.
According to the complaint, pharmacists encountered a variety of warning signs that could indicate inappropriate or potentially dangerous prescribing.
Some prescriptions were allegedly issued by prescribers who were already known within Walmart to be associated with suspected “pill mill” operations. Other prescriptions reportedly contained combinations of controlled substances or unusually high quantities and dosages of medications with significant potential for misuse.
Examples cited by the government included potentially dangerous combinations of opioids, combinations of opioids with non-opioid medications, repeated dispensing of high doses of frequently abused opioids, and requests for controlled substances to be filled earlier than scheduled.
The government alleged that these circumstances should have prompted additional scrutiny or refusal to dispense the prescriptions.
New Requirements for Walmart
In addition to the $50 million financial settlement, Walmart has entered into a memorandum of agreement with the DEA establishing additional requirements for the company's future handling of controlled substances.
Under the agreement, Walmart will be required to strengthen its systems for identifying and addressing potentially unlawful dispensing practices.
Among the measures included in the agreement are the establishment of a hotline that employees and patients can use to report suspected illegal dispensing of controlled substances.
Walmart must also proactively monitor dispensing patterns across its pharmacies. The goal is to identify unusual or potentially unlawful activity and take appropriate action when concerning patterns are detected.
The agreement additionally requires Walmart to establish procedures for reviewing prescribers who are suspected of engaging in illegal prescribing practices.
These measures are intended to provide stronger oversight of controlled-substance dispensing and create additional mechanisms for identifying potential problems before they result in further harm.
Broader Concerns About Opioid Oversight
The case highlights the important role pharmacies play in preventing the inappropriate distribution of controlled substances. Pharmacists and pharmacy organizations serve as an important checkpoint between prescribers and patients, with federal law requiring controlled-substance prescriptions to meet specific legal and professional standards.
The government's allegations against Walmart centered not simply on the existence of questionable prescriptions, but on whether the company had adequate systems in place to recognize warning signs and respond appropriately to concerns raised by its own pharmacy personnel.
The settlement also illustrates the continuing federal focus on strengthening controls throughout the prescription-drug supply chain. Effective oversight requires cooperation among prescribers, pharmacists, pharmacies, regulators, law enforcement agencies, and other healthcare professionals.
While the settlement resolves the government's allegations against Walmart, it also establishes additional compliance obligations intended to improve the company's future monitoring and reporting practices.
The United States was represented in the matter by attorneys from the Justice Department's Civil Division Enforcement & Affirmative Litigation Branch, along with attorneys from the U.S. Attorneys' Offices for the District of Delaware, Eastern District of North Carolina, Middle District of Florida, and Eastern District of New York.
The matter involved attorneys Katherine Ho, Kathleen Brunson, Meredith Reiter, Dylan Steinberg, Elizabeth Vieya, Andrew Kasper, Carolyn Tapie, and Elliot Schachner. Former Enforcement & Affirmative Litigation Branch investigator Amanda Graf also provided assistance.
The $50 million agreement represents another significant federal enforcement action involving the dispensing of prescription opioids and other controlled substances, while the additional monitoring and reporting requirements are intended to strengthen safeguards against inappropriate prescribing, diversion, and misuse.
Source: DEA